Nurix enrolls first patient in Phase 1b/2 CLL trial of BTK degrader bexobrutideg plus venetoclax
Nurix enrolled the first patient in a Phase 1b/2 study testing BTK degrader bexobrutideg with venetoclax in CLL/SLL. Trial results have not been presented; data are expected to guide future registrational development plans across CLL treatment lines. Initial focus is relapsed or refractory CLL, with potential expansion